2022
DOI: 10.3390/ph15091058
|View full text |Cite
|
Sign up to set email alerts
|

Design, Rational Repurposing, Synthesis, In Vitro Evaluation, Homology Modeling and In Silico Study of Sulfuretin Analogs as Potential Antileishmanial Hit Compounds

Abstract: Direct growth inhibition of infectious organisms coupled with immunomodulation to counteract the immunosuppressive environment might be a beneficial therapeutic approach. Herein, a library of sulfuretin analogs were developed with potential capabilities to inhibit production of the immunosuppressive PGE2 and elicit direct growth inhibition against Leishmania donovani; the major causative agent of the fatal visceral leishmaniasis. Amongst explored library members bearing diverse methoxy and/or hydroxy substitut… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
10

Relationship

5
5

Authors

Journals

citations
Cited by 13 publications
(5 citation statements)
references
References 28 publications
0
3
0
Order By: Relevance
“…Hit discovery and confirmation is an indispensable first step in early drug discovery [ 34 , 35 , 36 , 37 , 38 ]. While a hit compound would show the desired type of activity, its activity might be of low potential and/or it can possess undesirable effects.…”
Section: Resultsmentioning
confidence: 99%
“…Hit discovery and confirmation is an indispensable first step in early drug discovery [ 34 , 35 , 36 , 37 , 38 ]. While a hit compound would show the desired type of activity, its activity might be of low potential and/or it can possess undesirable effects.…”
Section: Resultsmentioning
confidence: 99%
“…In silico studies were conducted following literature protocols 32–36 as in supplementary information .…”
Section: Methodsmentioning
confidence: 99%
“…Repurposing (aka repositioning or reprofiling) is a well-acknowledged strategy in drug discovery that offers several advantages including saving time, money and resources that are needed to develop novel drugs from scratch [47][48][49][50][51][52]. This strategy is not limited to repurposing compounds for indications outside of clinically approved therapeutic areas, but extends also to previously studied molecules that have not been approved or even previously failed [19,53].…”
Section: Repurposing Rationalmentioning
confidence: 99%